Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells

Background/Aims: As the most lethal urological cancers, renal cell carcinoma (RCC) comprises a heterogeneous group of cancer with diverse genetic and molecular alterations. There is an unmet clinical need to develop efficacious therapeutics for advanced, metastatic and/or relapsed RCC. Here, we investigate whether anthelmintic drug Niclosamide exhibits anticancer activity and synergizes with targeted therapy Sorafenib in suppressing RCC cell proliferation. Methods: Cell proliferation and migration were assessed by Crystal violet staining, WST-1 assay, cell wounding and cell cycle analysis. Gene expression was assessed by qPCR. In vivo anticancer activity was assessed in xenograft tumor model. Results: We find that Niclosamide effectively inhibits cell proliferation, cell migration and cell cycle progression, and induces apoptosis in human renal cancer cells. Mechanistically, Niclosamide inhibits the expression of C-MYC and E2F1 while inducing the expression of PTEN in RCC cells. Niclosamide is further shown to synergize with Sorafenib in suppressing RCC cell proliferation and survival. In the xenograft tumor model, Niclosamide is shown to effectively inhibit tumor growth and suppress RCC cell proliferation. Conclusions: Niclosamide may be repurposed as a potent anticancer agent, which can potentiate the anticancer activity of the other agents targeting different signaling pathways in the treatment of human RCC.

[1]  L. Ming,et al.  Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma , 2017, Cellular Physiology and Biochemistry.

[2]  R. Figlin,et al.  ONCONEPHROLOGY: Targeted therapies for renal cell carcinoma , 2017 .

[3]  T. He,et al.  BMP9 induces osteogenesis and adipogenesis in the immortalized human cranial suture progenitors from the patent sutures of craniosynostosis patients , 2017, Journal of cellular and molecular medicine.

[4]  T. He,et al.  Characterization of retroviral infectivity and superinfection resistance during retrovirus-mediated transduction of mammalian cells , 2017, Gene Therapy.

[5]  T. He,et al.  Noncanonical Wnt signaling plays an important role in modulating canonical Wnt-regulated stemness, proliferation and terminal differentiation of hepatic progenitors , 2017, Oncotarget.

[6]  F. Liu,et al.  Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC) , 2017, Oncotarget.

[7]  R. Montironi,et al.  The prospect of precision therapy for renal cell carcinoma. , 2016, Cancer treatment reviews.

[8]  T. He,et al.  A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities , 2016, Cellular Physiology and Biochemistry.

[9]  Maryam K. Mohammed,et al.  Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance , 2016, Genes & diseases.

[10]  Maryam K. Mohammed,et al.  Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells , 2015, Scientific Reports.

[11]  Maryam K. Mohammed,et al.  The Calcium-Binding Protein S100A6 Accelerates Human Osteosarcoma Growth by Promoting Cell Proliferation and Inhibiting Osteogenic Differentiation , 2015, Cellular Physiology and Biochemistry.

[12]  Maryam K. Mohammed,et al.  The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: Implications in targeted cancer therapies , 2015, Laboratory Investigation.

[13]  R. Montironi,et al.  Metabolic alterations in renal cell carcinoma. , 2015, Cancer treatment reviews.

[14]  T. He,et al.  A Novel Organ Culture Model of Mouse Intervertebral Disc Tissues , 2015, Cells Tissues Organs.

[15]  T. He,et al.  The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways. , 2015, Current cancer drug targets.

[16]  Yinglin Xia,et al.  TqPCR: A Touchdown qPCR Assay with Significantly Improved Detection Sensitivity and Amplification Efficiency of SYBR Green qPCR , 2015, PloS one.

[17]  R. Srinivasan,et al.  Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology , 2015, Current opinion in oncology.

[18]  Jie Zhang,et al.  S100 Calcium-Binding Protein A6 Promotes Epithelial-Mesenchymal Transition through β-Catenin in Pancreatic Cancer Cell Line , 2015, PloS one.

[19]  T. Baudino,et al.  Targeted Cancer Therapy: The Next Generation of Cancer Treatment. , 2015, Current drug discovery technologies.

[20]  T. He,et al.  Sustained high level transgene expression in mammalian cells mediated by the optimized piggyBac transposon system , 2015, Genes & diseases.

[21]  R. Srinivasan,et al.  New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease , 2015, Clinical Cancer Research.

[22]  E. Lengyel,et al.  WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer , 2014, Oncogene.

[23]  Yonghe Li,et al.  Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. , 2014, Cancer letters.

[24]  C. Landen,et al.  Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. , 2014, Gynecologic oncology.

[25]  T. He,et al.  The piggyBac Transposon-Mediated Expression of SV40 T Antigen Efficiently Immortalizes Mouse Embryonic Fibroblasts (MEFs) , 2014, PloS one.

[26]  Yezi Zhu,et al.  Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[27]  T. He,et al.  Characterization of Constitutive Promoters for piggyBac Transposon-Mediated Stable Transgene Expression in Mesenchymal Stem Cells (MSCs) , 2014, PloS one.

[28]  T. He,et al.  Targeting BMP9-promoted human osteosarcoma growth by inactivation of notch signaling. , 2014, Current cancer drug targets.

[29]  Yonghe Li,et al.  Effect of Niclosamide on Basal-like Breast Cancers , 2014, Molecular Cancer Therapeutics.

[30]  V. Kríz,et al.  Monensin Inhibits Canonical Wnt Signaling in Human Colorectal Cancer Cells and Suppresses Tumor Growth in Multiple Intestinal Neoplasia Mice , 2014, Molecular Cancer Therapeutics.

[31]  P. Yin,et al.  Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth , 2014, Fertility and Sterility.

[32]  Yuquan Wei,et al.  The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model , 2014, PloS one.

[33]  G. Sica,et al.  Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer , 2013, Molecular Cancer Therapeutics.

[34]  Cheng-Chang Chang,et al.  Drug Screening Identifies Niclosamide as an Inhibitor of Breast Cancer Stem-Like Cells , 2013, PloS one.

[35]  W. Curran,et al.  Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer , 2013, PloS one.

[36]  Sahdeo Prasad,et al.  Cancer drug discovery by repurposing: teaching new tricks to old dogs. , 2013, Trends in pharmacological sciences.

[37]  R. Fimmers,et al.  Anticancer Effects of Niclosamide in Human Glioblastoma , 2013, Clinical Cancer Research.

[38]  W. Curran,et al.  Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer , 2013, Molecular Cancer Therapeutics.

[39]  T. He,et al.  Cross-talk between EGF and BMP9 signalling pathways regulates the osteogenic differentiation of mesenchymal stem cells , 2013, Journal of cellular and molecular medicine.

[40]  B. Faircloth,et al.  Primer3—new capabilities and interfaces , 2012, Nucleic acids research.

[41]  K. Nephew,et al.  Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide , 2012, Molecular Cancer Therapeutics.

[42]  G. Piazza,et al.  Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway , 2011, PloS one.

[43]  J. Qin,et al.  Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma , 2011, Oncogene.

[44]  D. Scudiero,et al.  Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. , 2011, Journal of the National Cancer Institute.

[45]  Wei Chen,et al.  Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. , 2011, Cancer research.

[46]  T. He,et al.  Tetrandrine Inhibits Wnt/β-Catenin Signaling and Suppresses Tumor Growth of Human Colorectal Cancer , 2011, Molecular Pharmacology.

[47]  Wei Chen,et al.  Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[48]  T. He,et al.  Insulin-like Growth Factor 2 (IGF-2) Potentiates BMP-9-Induced Osteogenic Differentiation and Bone Formation , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[49]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[50]  Yanli Jin,et al.  Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. , 2010, Cancer research.

[51]  T. He,et al.  Retinoic acid signalling induces the differentiation of mouse fetal liver‐derived hepatic progenitor cells , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[52]  Yu-Chih Liang,et al.  The autonomous notch signal pathway is activated by baicalin and baicalein but is suppressed by niclosamide in K562 cells , 2009, Journal of cellular biochemistry.

[53]  A. Montag,et al.  Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects , 2008, Laboratory Investigation.

[54]  T. Wilt,et al.  Targeted therapy for advanced renal cell carcinoma. , 2008, The Cochrane database of systematic reviews.

[55]  L. Costa,et al.  Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. , 2007, The oncologist.

[56]  T. Libermann,et al.  Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead , 2007, Clinical Cancer Research.

[57]  C. Heizmann,et al.  Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. , 2005, Cancer letters.

[58]  W. Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2004, Clinical Cancer Research.

[59]  A. Montag,et al.  Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcoma , 2002, International journal of cancer.

[60]  R. Motzer,et al.  Renal-cell carcinoma. , 1996, The New England journal of medicine.

[61]  Min Huang,et al.  Molecularly targeted cancer therapy: some lessons from the past decade. , 2014, Trends in pharmacological sciences.

[62]  Y. Quan,et al.  Medical genetic inspirations for anticancer drug repurposing. , 2014, TIPS - Trends in Pharmacological Sciences.

[63]  Umberto Capitanio,et al.  Renal Cancer , 2011 .

[64]  W. Linehan,et al.  Unique Opportunity for Disease-based Therapy* , 2009 .

[65]  A. Montag,et al.  An Orthotopic Model of Human Osteosarcoma Growth and Spontaneous Pulmonary Metastasis , 2005, Clinical & Experimental Metastasis.

[66]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[67]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.